Physician profile
Eileen Digregorio
NPI 1821005687
$4,097.11
in general payments reported to CMS, 2019-2025
24 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $755 · 2021: $913 · 2022: $858 · 2023: $608 · 2024: $275 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.38 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $630.34 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $506.52 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $440.52 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $429.46 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $204.66 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $165.73 | 2019-2022 | |
| Amarin Pharma, INC. | $145.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $93.64 | 2019-2021 | |
| Allergan, INC. | $87.02 | 2019-2020 | |
| Bausch Health US, LLC | $82.42 | 2019-2022 | |
| Abbott Laboratories | $66.53 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $66.26 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $45.43 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.12 | 2020-2024 | Xifaxan |
| Astellas Pharma US INC | $37.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $31.32 | 2022-2024 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $31.12 | 2021 | |
| Eisai INC. | $21.18 | 2021 | |
| Corcept Therapeutics | $20.48 | 2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Digregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.